Triple-Action antibody takes on advanced cancers
NCT ID NCT06741644
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 4 times
Summary
This study tests a new drug called CS2009, a tri-specific antibody that targets three proteins (PD-1, VEGFA, and CTLA-4) to fight advanced solid tumors. The trial has two phases: first, finding the safest dose, then expanding to see how well it shrinks tumors. About 660 adults with cancers like lung, kidney, or liver cancer that cannot be surgically removed are being recruited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Alfred Hospital (Alfred Health)
RECRUITINGMelbourne, Australia
-
Anhui Provincial Hospital
RECRUITINGHefei, China
-
Austin Hospital (Austin Health)
RECRUITINGMelbourne, Australia
-
Beijing Cancer Hospital
RECRUITINGBeijing, China
-
Blacktown Hospital
RECRUITINGSydney, Australia
-
Central Hospital Affiliated to Shandong First Medical University
RECRUITINGJinan, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, China
-
Hunan Cancer Hospital
RECRUITINGChangsha, China
-
Icon Cancer Centre South Brisbane
RECRUITINGSouth Brisbane, Australia
-
Jilin Cancer Hospital
RECRUITINGChangchun, China
-
Linyi Cancer Hospital
RECRUITINGLinyi, China
-
Macquarie University Hospital
RECRUITINGSydney, Australia
-
Monash Medical Centre (Monash Health)
RECRUITINGMelbourne, Australia
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
-
Nanjing Drum Tower Hospital
RECRUITINGNanjing, China
-
Peter Maccallum Cancer Centre Research
RECRUITINGMelbourne, Australia
-
START Los Angeles, LLC
RECRUITINGLos Angeles, California, 90025, United States
-
Scientia Clinical Research Ltd
RECRUITINGSydney, Australia
-
Shanghai East Hospital
RECRUITINGShanghai, China
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, China
-
Sichuan Cancer Hospital
RECRUITINGChengdu, China
-
Sun Yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
-
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITINGGuangzhou, China
-
The First Affiliated Hospital of Nanchang University
RECRUITINGNanchang, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, China
-
West China Hospital of Sichuan University
RECRUITINGChengdu, China
-
Xuzhou Central Hospital
RECRUITINGXuzhou, China
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a pill outsmart Tumors' defenses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?